Connect with us

Press Release

BitMax.io Announced the Primary Listing of Yield App to Support DeFi Banking

Published

5 years ago

on

BitMax.io (BTMX.com), an industry-leading digital asset trading platform built by Wall Street quant trading veterans, has announced the primary listing of Yield App (YLD) under the trading pair of YLD/USDT on Dec 14 at 9:00 a.m. EST.

YIELD, a FinTech company licensed and regulated by Mwali International Services Authority, offers Defi-based banking services and high-yield investment solutions using crypto or traditional currencies with an objective to make the full potential of Defi accessible to everyone. Leveraging their intuitive app and web platform, users worldwide can start earning up to 20% APY without experiencing a lengthy, complex, and costly learning process.

On the backend, YIELD’s team is constantly evaluating the profitable market-neutral strategies such as liquidity mining, arbitrage, margin, and collateralized lending. The highly sophisticated risk management process will also help investors realize portfolio diversification within a trusted environment.

At the core of YIELD’s strategy is the YLD utility token, which allows users to considerably boost their APYand support the ecosystem. While YIELD offers a minimum APY of 12%, users will be able to boost it to 20% by holding YLD on the platform with signing up for the Loyalty & Rewards program.

YIELD’s team brings together veterans from investment banking, blockchain, and cybersecurity with core members from fintech payment providers like Paxful and Wirex. The team is backed by leading blockchain investment institutions, including Alphabit Fund, Digital Strategies, and PALcapital. 

About BitMax.io 

Launched in August 2018, BitMax.io is a leading digital asset trading platform with a broad range of financial products and services for both retail and institutional clients, with robust design ranging from innovative volatility products to margin trading, derivatives trading, staking products, and other investment solutions.

For more information and updates, please visit:

Website: https://bitmax.io/

Twitter: https://twitter.com/BitMax_Official

Telegram: https://t.me/BitMaxioEnglishOfficial

Medium: https://medium.com/bitmax-io

About Yield App

Yield is a Mwali licensed and regulated FinTech company that provides an innovative platform to bridge the gap between traditional and decentralized finance. The YLD utility token allows users to boost their APY, earn interest, and support YIELD’s ecosystem.

For more information and updates, please visit:

Website: https://www.yield.app

Twitter: https://twitter.com/yieldapp

Telegram: https://t.me/yieldapp

Reddit: https://www.reddit.com/r/Yield_App/

About Author

Alex Jacob

Alex Jacob is a literature author. He was born in Chicago. Alex passion is writing news articles. He writes number of articles and published it.

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China

Published

23 minutes ago

on

December 15, 2025

By

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”), with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product.

 

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa (HS) and prurigo nodularis in several countries outside China. A Phase 2 clinical trial for the treatment of asthma is also ongoing.

 

In March 2023, Incyte announced that povorcitinib met the primary endpoint in a global multi-center Phase 2b clinical trial for non-segmental vitiligo. Results showed that after 24 weeks of treatment, compared with vehicle, total body repigmentation of patients treated with povorcitinib once daily was significantly improved. Furthermore, according to the extended Phase 2b trial, longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation with a favorable tolerability profile[1]. 

 

In August 2025, Dermavon received the drug clinical trial approval notice issued by NMPA to conduct clinical trials of povorcitinib for the treatment of non-segmental vitiligo and other indications. Dermavon has initiated the clinical development of the Product in China and may consider further initiating clinical development of povorcitinib in China for the treatment of skin-related diseases such as HS and prurigo nodularis in the future.

 

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[2]. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. If approved in China, povorcitinib could provide a differentiated treatment option for patients with non-segmental vitiligo.

 

The Product’s inclusion in the list of Breakthrough Therapeutic Drugs is expected to accelerate its development and review process in mainland China. If approved for marketing in China, the Product has the potential to synergize with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and the innovative drug currently under New Drug Application (NDA) review ruxolitinib phosphate cream, helping the product to quickly realize its clinical and commercial value and benefit more patients with skin diseases. Furthermore, if approved, the Product, together with topical ruxolitinib phosphate cream, will provide vitiligo patients with differentiated and comprehensive treatment options.

 

The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to the Group (excluding Dermavon and its subsidiaries).

 

About CMS

 

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. 

 

Reference：

  1. Results from a global multi-center Phase 2b clinical trial of the product for non-segmental vitiligo indication can be found on the Incyte official website: https://investor.incyte.com/news-releases/news-release-details/incyte-an…
  2. Datas are from the China Insights Consultancy (CIC) report

 

CMS Disclaimer and Forward-Looking Statements

 

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

How to Get Rid of Pimples Launches Comprehensive Ebook to Help People Achieve Clear, Healthy Skin Naturally

Published

53 minutes ago

on

December 15, 2025

By

Georgia, 15th Dec 2025 — How to Get Rid of Pimples, a Germany-based skincare knowledge brand founded by Marcel Schneider, proudly announces the launch of its new ebook, “How to Get Rid of Pimples”—a practical, research-backed guide designed to help individuals eliminate acne safely, effectively, and permanently. Available exclusively at How-to-get-rid-of-pimples.com, the ebook offers one of the most accessible and complete solutions for people struggling with breakouts.

Acne remains one of the most common skin concerns worldwide, affecting both teenagers and adults. While the internet is filled with conflicting advice, harsh chemical solutions, and temporary fixes, Marcel Schneider set out to create a resource that gives readers real, science-backed guidance. The newly released ebook compiles proven skincare strategies, daily routines, diet adjustments, and lifestyle practices aimed at addressing the root causes of pimples—not just the symptoms.

A Clear, Action-Driven Approach to Acne-Free Skin

The ebook breaks down complex dermatological concepts into easy-to-understand steps, making it ideal for beginners and skincare enthusiasts alike. Readers will learn:

  • How pimples form and what truly triggers breakouts
  • The most effective home remedies backed by science
  • Which skincare ingredients to use — and which ones to avoid
  • The correct order for applying products
  • Common lifestyle mistakes that worsen acne
  • Diet and nutrition tips that support clear skin
  • Daily, weekly, and monthly routines for long-term results

Unlike generic online articles, Marcel Schneider’s ebook provides structured, actionable solutions, allowing readers to quickly implement changes and track their skincare progress.

Why This Ebook Stands Out

“What makes this guide different is its simplicity,” said Marcel Schneider, creator of How to Get Rid of Pimples. “People are overwhelmed by so many products and opinions. I wanted to provide a roadmap that actually works—without expensive treatments or confusing terminology. The goal is to help anyone, no matter their skin type, finally gain confidence in their skin.”

The ebook also highlights natural and budget-friendly methods suitable for students, busy professionals, and individuals with sensitive skin. Each recommendation is designed to be practical, safe, and customizable.

Optimized for Real Results

Visitors can access the ebook exclusively through the official website, How-to-get-rid-of-pimples.com, where Marcel Schneider also provides additional educational content. The site aims to become a trusted resource for acne solutions, offering simplified skincare knowledge backed by research and practical experience.

With millions searching online every day for ways to clear their skin, this ebook launches at a critical time. Its holistic approach aligns with the growing global demand for non-toxic, evidence-based skincare solutions.

About “How to Get Rid of Pimples”

How to Get Rid of Pimples is a skincare information brand based in Germany, dedicated to helping people overcome acne through reliable, science-supported knowledge. Founded by skincare enthusiast Marcel Schneider, the company focuses on providing accessible digital education, actionable advice, and simplified skincare routines. The ebook, “How to Get Rid of Pimples,” is the company’s flagship publication, aimed at empowering individuals to understand and treat the real causes of acne.

Media Contact

Organization: How to Get Rid of Pimples

Contact Person: Marcel Schneider

Website: https://how-to-get-rid-of-pimples.com/

Email: Send Email

Country:Georgia

Release id:39080

The post How to Get Rid of Pimples Launches Comprehensive Ebook to Help People Achieve Clear, Healthy Skin Naturally appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

KeyCrew Media Selects Rob Marucci and Better Living Realty LLC as Verified Expert for Connecticut Real Estate Markets and Innovative Property Preparation

Published

53 minutes ago

on

December 15, 2025

By

KeyCrew Media, a real estate analytics and media network, has selected Rob Marucci, Broker-Owner of Better Living Realty LLC, as a KeyCrew Verified Expert

Middlebury, Connecticut, United States, 15th Dec 2025 – KeyCrew Media, a real estate analytics and media network, has selected Rob Marucci, Broker-Owner of Better Living Realty LLC, as a KeyCrew Verified Expert. Marucci and Better Living Realty will contribute data-driven analysis on Connecticut housing markets, property value optimization, and innovative real estate service models.

Better Living Realty LLC brings a distinctive approach to real estate through its “Curb to Close” program—a zero-upfront-cost property preparation service. Under Marucci’s leadership as both licensed broker and general contractor, the 30-agent brokerage offers an alternative approach to how properties are prepared for market across Connecticut and Rhode Island.

Established in 2010 during the recession, Better Living Realty has grown into a full-service real estate company serving New Haven and Litchfield Counties in Connecticut, plus select Rhode Island markets. The brokerage specializes in properties ranging from $500,000 to $1 million and differentiates itself through hands-on service that demonstrates measurable value in an industry facing increased scrutiny.

The company’s competitive advantage stems from Marucci’s unique dual licensing as both real estate broker and general contractor—a rare combination that allows Better Living Realty to offer comprehensive in-house services including power washing, painting, landscaping, flooring, electrical work, plumbing, and post-inspection repairs. All improvements are managed with a trusted contractor team, with costs paid only at closing rather than requiring upfront investment from sellers.

In one illustrative example, a Waterbury estate property that had been vacant for five years had an initial contract in place at $202,000. Following strategic improvements totaling approximately $10,700, the property closed with a final contract at $325,000. Another recent project involved strategic updates to convert a property from attracting primarily investor interest to appealing to owner-occupant buyers. Individual results vary based on property condition, market timing, and other factors. Past performance does not guarantee future results.

Marucci brings 18 years of real estate experience spanning the 2008 market crash, pandemic-era dynamics, and current market corrections. His journey began in 2007 when he purchased three investment properties immediately before the crash, then pivoted to become a full-time broker in 2010. He holds a bachelor’s degree in economics from the University of Connecticut and maintains an active portfolio of 14 investment properties, including vacation rentals in Rhode Island’s coastal markets. This dual perspective as both practicing agent and active investor informs Better Living Realty’s client-focused approach and market analysis.

“I’m honored that Better Living Realty has been recognized as a Verified Expert,” said Rob Marucci. “Connecticut’s real estate market is evolving from pandemic-era dynamics back to fundamentals where preparation matters again. Through our Curb to Close program and hands-on market experience, we work to help clients navigate this transition. I’m excited to share insights on market trends, innovative service models, and practical strategies for both consumers and industry professionals in this changing landscape.”

Marucci and Better Living Realty’s areas of expertise include:

  • Connecticut Real Estate Markets — Specialized knowledge in New Haven and Litchfield Counties, with deep understanding of inventory trends, pricing dynamics, and buyer behavior
  • Property Value Optimization — Strategies for preparing properties for market through cost-effective improvements
  • Innovative Real Estate Service Models — Zero-upfront-cost property preparation programs and alternative service delivery approaches
  • Real Estate Investment Strategy — Guidance on cash flow analysis, property management considerations, and portfolio building informed by active investment experience
  • Market Cycle Navigation — Expertise spanning multiple market cycles including 2008 crash, pandemic boom, and current corrections

About Better Living Realty LLC

Better Living Realty LLC is a full-service real estate brokerage established in 2010, serving New Haven, Hartford and Litchfield Counties in Connecticut plus Rhode Island markets. Led by Broker-Owner Rob Marucci, the 30-agent team specializes in residential properties from $500,000 to $1 million and offers comprehensive services including traditional buyer/seller representation, the innovative Curb to Close property preparation program, investment consulting, and post-inspection issue resolution. The brokerage differentiates itself through measurable value delivery, in-house contractor services, and deep local market expertise built over 15 years of operation. Website: www.betterlivingrealtyllc.com

About KeyCrew Media

KeyCrew Media is the next generation real estate intelligence platform that leverages AI-powered analytics and first-person reporting from verified experts to produce forward-looking insights across local markets and niche asset classes. Proprietary market reporting is delivered through KeyCrew’s growing portfolio of niche media properties – including KeyCrew Journal, NextAsset News, and other specialized publications – as well as selectively syndicated to media partners that influence industry decision-makers. Learn more at keycrew.co

Media Contact

Organization: Better Living Realty LLC

Contact Person: Heather Hook

Website: https://www.betterlivingrealtyllc.com/

Email: Send Email

City: Middlebury

State: Connecticut

Country:United States

Release id:38938

The post KeyCrew Media Selects Rob Marucci and Better Living Realty LLC as Verified Expert for Connecticut Real Estate Markets and Innovative Property Preparation appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us